Analyst Research on Gilead Sciences Inc. and Human Genome Sciences Inc. -- Biotechnology Sector Benefits When Regulators Say 'OK
May 27 2011 - 8:50AM
Marketwired
www.stockcall.com/ offers investors comprehensive research on the
Biotechnology industry and has completed analytical research on
Gilead Sciences Inc. (NASDAQ: GILD) and
Human Genome Sciences Inc. (NASDAQ: HGSI).
Register with us today at www.stockcall.com/ to have free access to
these researches.
The biotechnology and pharmaceutical sectors are usually quite
diverse and company specific in their happenings. The success of
each company depends on a wide range of independent factors along
with their ability to acquire regulatory approval for marketing and
selling drugs. A good example of this can be seen in the recent
news surrounding Gilead Sciences Inc. and Human Genome Sciences
Inc. Register now at
https://stockcall.com/development/stockcall/page.php?name=register.html
to have free access to our reports on the Biotechnology
industry.
www.stockcall.com/ is an online platform where investors doing
their due-diligence on the Biotechnology industry can have easy and
free access to our analyst research and opinions on Gilead Sciences
Inc. and Human Genome Sciences Inc.; all investors need to do is
register for a complimentary membership at
https://stockcall.com/development/stockcall/page.php?name=register.html.
Gilead Sciences has been dealing with protestors that want the
company to lower its prices for AID's medication programs in the
United States. All companies that make treatments typically walk
the high wire between fiscal success and public altruism. The
company, a major player in the HIV market, recently has been
developing a drug with great efficacy at preventing the
transmission of the disease between partners. Investors looking for
free research on Gilead Sciences Inc. are
welcome to sign up at www.stockcall.com/GILD270511.pdf for our new
report.
In this sector, what is good for patients is also good for the
pocketbooks. For Human Genome, the big news lately has been the
European approval of human use for their Lupus Drug,
Benlysta-belimumab. Regulatory approval is usually the pay off for
large amounts of time and money invested in developing a product as
now it can be put on the market and begin accruing revenue.
Investors looking for complimentary research on Human Genome Sciences Inc. are welcome to sign up at
www.stockcall.com/HGSI270511.pdf for our new report.
Visit www.stockcall.com/ to see how companies in this industry
have grown over the past years and how they are expected to perform
in the future.
About StockCall.com StockCall.com is a
financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the
headlines.
Contact Person: William T. Knight
stockcall2010@gmail.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024